Rayscape, a Romanian healthtech company, has secured EUR 1.5 million in non-repayable EU funding to develop Rayscape TAP-CT, an AI-powered platform for analyzing oncology CT scans. The project, co-funded by the European Union, aims to advance AI capabilities in oncological imaging.
TL;DR
- Rayscape secures EUR 1.5M in EU funding for Rayscape TAP-CT, an AI platform for oncology CT analysis.
- The project aims to expand AI capabilities in oncological imaging, covering thorax-abdomen-pelvis (TAP) CT examinations.
- Rayscape TAP-CT will support radiologists in diagnosis and monitoring, ultimately contributing to better patient outcomes.
What happened
Edgefront Technologies, part of the same group as Rayscape, has signed a funding agreement with the Romanian Ministry of Investments and European Projects. The agreement is for the development of Rayscape TAP-CT, an AI-driven software product designed to analyze CT examinations in oncology.
The project, with a total value of approximately EUR 2 million, includes EUR 1.46 million in non-repayable EU funding and EUR 0.54 million in the beneficiary's own contribution. The project will run for 36 months, from July 2026 to July 2029.
Rayscape TAP-CT represents a significant step in Rayscape's evolution, expanding its AI capabilities to cover the entire thorax-abdomen-pelvis (TAP) CT examination. This move enables the detection and longitudinal tracking of oncological lesions in the abdomen and pelvis, complementing the company's existing capabilities in chest imaging.
Why it matters
The funding and development of Rayscape TAP-CT highlight the growing importance of AI in medical imaging, particularly in oncology. By providing radiologists with a trusted tool for diagnosis and monitoring, Rayscape aims to support better-informed decisions for patients.
The project's focus on advancing from specific pathology models to a 3D model capable of analyzing the entire CT examination demonstrates Rayscape's commitment to innovation. This integrated approach has the potential to deliver more relevant information in less time, addressing a critical need in oncology.
For developers and startups in the AI and healthcare sectors, Rayscape's progress serves as a case study in leveraging AI to enhance medical imaging. The project's success could pave the way for similar advancements in other areas of healthcare, driving further investment and innovation.
Key facts
- Rayscape secures EUR 1.5 million in non-repayable EU funding for the Rayscape TAP-CT project.
- The total project value is approximately EUR 2 million, with EUR 1.46 million provided by the EU and EUR 0.54 million from the beneficiary's own contribution.
- The project will run for 36 months, from July 2026 to July 2029.
- Rayscape TAP-CT aims to cover the entire thorax-abdomen-pelvis (TAP) CT examination, expanding beyond chest imaging to include the abdomen and pelvis.
- The project will advance Rayscape's AI capabilities from Technology Readiness Level (TRL) 4 to TRL 9, enabling real-world clinical deployment.
- Rayscape's existing technologies are already in use across more than 20 countries, demonstrating the company's established presence in the healthtech sector.
- The project is co-funded by the European Union under the Health Programme 2021–2027, within the framework of STEP (Strategic Technologies for Europe Platform).
Context
Rayscape's focus on AI-driven medical imaging aligns with the broader trend of leveraging AI to enhance healthcare outcomes. As oncology cases become increasingly numerous and complex, the need for advanced diagnostic tools becomes more pressing.
The development of Rayscape TAP-CT reflects a growing interest in integrated AI solutions that can provide a comprehensive view of medical examinations. This approach has the potential to revolutionize the way radiologists and physicians diagnose and monitor diseases.
For investors, the success of Rayscape TAP-CT could signal opportunities in the AI and healthcare sectors. The project's focus on real-world clinical deployment and its potential to improve patient outcomes make it a compelling case for further investment.
